Semaxen
Generic Name
Semaglutide
Manufacturer
Hypothetical Manufacturer (e.g., Novo Nordisk)
Country
Denmark (origin of Semaglutide)
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| semaxen 3 mg tablet | ৳ 600.00 | N/A |
Description
Overview of the medicine
Semaglutide 3 mg tablet is an oral glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus to improve glycemic control in adults, as an adjunct to diet and exercise. It may also be used to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Uses & Indications
Dosage
Adults
Initial dose is 3 mg orally once daily for 1 month. After 1 month, increase the dose to 7 mg orally once daily. If additional glycemic control is needed after at least 1 month on 7 mg, the dose may be increased to 14 mg orally once daily. (Note: Semaxen-3-mg-tablet is the initial dose).
Elderly
No dose adjustment is required based on age. However, experience in patients ≥75 years is limited.
Renal_impairment
No dose adjustment is recommended for patients with mild, moderate, or severe renal impairment. Not recommended for use in patients with End-Stage Renal Disease (ESRD).
How to Take
Take Semaxen at least 30 minutes before the first food, beverage, or other oral medications of the day, with no more than 120 mL (4 ounces) of plain water. Swallow the tablet whole. Do not split, crush, or chew the tablet.
Mechanism of Action
Semaglutide is a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor. It increases glucose-dependent insulin secretion, decreases glucagon secretion, and delays gastric emptying. It also acts on the satiety centers in the brain, leading to reduced appetite and caloric intake, which can contribute to weight loss.
Pharmacokinetics
Onset
Effects on glucose reduction begin relatively quickly, but steady-state plasma concentrations are achieved after 4-5 weeks of daily administration.
Excretion
The primary routes of excretion are via urine (approx. 2/3) and feces (approx. 1/3) as metabolites and small amounts of intact semaglutide.
Half life
Approximately 1 week (about 7 days), allowing for once-daily dosing.
Absorption
Oral bioavailability is low (0.4-1.6%) due to the peptide nature but enhanced by an absorption enhancer (SNAC). Peak plasma concentration is reached approximately 1 hour post-dose.
Metabolism
Extensively metabolized via proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain, with no specific organ identified as the primary site of metabolism.
Side Effects
Contraindications
- •Personal or family history of medullary thyroid carcinoma (MTC).
- •Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- •Known hypersensitivity to semaglutide or any of the excipients.
Drug Interactions
Warfarin and other coumarin derivatives
Semaglutide may enhance the anticoagulant effect of warfarin. Increased INR monitoring should be performed when initiating semaglutide in patients on warfarin.
Oral medications with a narrow therapeutic index
Semaglutide delays gastric emptying, which may affect the absorption of concomitantly administered oral medications. Exercise caution when co-administering with medications that require rapid gastrointestinal absorption or have a narrow therapeutic index.
Insulin secretagogues (e.g., sulfonylureas) or insulin
When Semaxen is used with an insulin secretagogue (e.g., sulfonylurea) or insulin, the risk of hypoglycemia is increased. A dose reduction of the insulin secretagogue or insulin may be required.
Storage
Store below 30°C. Protect from moisture and light. Keep out of the reach of children.
Overdose
In the event of an overdose, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms. A prolonged period of observation and treatment may be necessary, taking into account the long half-life of semaglutide.
Pregnancy & Lactation
Pregnancy: Available data are insufficient to establish a drug-associated risk for major birth defects or miscarriage. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Discontinue Semaxen at least 2 months before a planned pregnancy due to the long half-life. Lactation: Unknown if Semaxen is excreted in human milk; not recommended during breastfeeding.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from manufacturing date.
Availability
Pharmacies, Hospitals
Approval Status
FDA Approved
Patent Status
Patented
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
